SymBio Pharmaceuticals

107 employees

Also known as:

4582-jp

symbio 制药

4582

SymBio Pharmaceuticals Ltd is a biopharmaceutical company engaged in manufacturing and commercializing drugs for oncology, hematology, and pain management.

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

48.0%

Phase 2

36.0%

Phase 3

12.0%

Trial Status Distribution

Completed

76.0%

Recruiting

4.0%

Suspended

4.0%

Terminated

12.0%

Withdrawn

4.0%

Clinical Trials

Trials sponsored by this organization (25)

A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Phase 3

Recruiting

interventional

Mar 2026180 participants

A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma

Phase 1

Suspended

interventional

Jun 202543 participants

Study to Confirm of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation

Phase 2

Terminated

interventional

Oct 20221 participant

A Phase 2a Study of IV BCV in Subjects With Adenovirus Infection

Phase 2

Completed

interventional

Aug 202153 participants

Drug-Drug Interaction Study of Intravenous Administration of SyB V-1901 and Cyclosporine in Japanese Healthy Subjects

Phase 1

Completed

interventional

Nov 202013 participants

Follow-up Study of SyB L-0501 in Combination With Rituximab to Treat DLBCL

Completed

observational

Mar 202025 participants

Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma

Phase 1

Completed

interventional

Apr 201937 participants

SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors

Phase 1

Completed

interventional

May 201818 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations